Page 23 - Cipla
Cipla arm recalls multiple lots of antidepressant drug from US market
The report, however, did not mention the quantity of the product
 "Cipla arm recalls multiple lots of antidepressant drug from US market")
Cipla stock: Healthy momentum in sales indicates strong earnings visibility
Cipla's relatively late entry into the US market is proving a blessing
 "Cipla stock: Healthy momentum in sales indicates strong earnings visibility")
Cipla rebounds after clarification on USFDA observations for Goa unit
The stock moved higher to Rs 558, bouncing back 7% from its early morning low of Rs 523 on the BSE.
 "Cipla rebounds after clarification on USFDA observations for Goa unit")
Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline
Companies to focus on complex products as tough competition in generics, customer consolidation impact profits
 "Pricing woes force Cipla, Glenmark, Lupin to go slow on US drug pipeline")
Cipla gains 7% on healthy operational performance in Q3
The stock surged 7% to Rs 608 after the EBITDA margins in December quarter improved to 20.9% from 18.6% in year ago quarter and 19.7% in previous quarter.
Cipla stands out in a gloomy sector as revenue swells 15% to Rs 16 bn
Improving prospects of US business to drive the company's earnings
 "Cipla stands out in a gloomy sector as revenue swells 15% to Rs 16 bn")
Business for posterity
Companies must create value through transformational impact on the planet
Cipla battles perceptions in a new campaign
The pharma major engages directly with patients, addresses social stigma and environmental concerns to expand the brand footprint in respiratory diseases
 "Cipla battles perceptions in a new campaign")
Cipla shines in gloomy pharma pack, biggest beneficiary of faster approvals
A low base in the US also means lower risks of price erosion, but as the company builds up its product pipeline expect earnings to improve
Cipla gets USFDA nod to market generic version of cancer drug Dacogen
It is indicated for treatment of patients with myelodysplastic syndromes
Cipla's US sales get boost with limited competition drugs
In Oct, it received the nod for a generic version of limited competition drug Renvela, used to treat kidney disease
Cipla gains 3% on final approval for generic Pulmicort Respules
The company has received final approval from the USFDA to market a generic version of Astrazeneca's Pulmicort Respules.
 "Cipla gains 3% on final approval for generic Pulmicort Respules")
Cipla's consistent margin gains stand out
Sales growth, benefits from operating leverage led to an in-line performance
Cipla hits 52-week high ahead of Q2 results
The stock moved higher to its 52-week high of Rs 661, up 3% on the BSE, ahead of its Q2FY18 results on Tuesday, November 7, 2017
Cipla ring-fences promoter holding
The promoter shareholding is valued at over Rs 16,600 crore
 "Cipla ring-fences promoter holding")
Cipla an outlier among pharma majors
Healthy outlook on strong margins, niche product launches and traction in key regulatory markets
Cipla surges 6% after stellar Q1 on healthy operating performance
Cipla was the largest gainer among Sensex and Nifty50 stocks at 11:01 am
 "Cipla surges 6% after stellar Q1 on healthy operating performance")
Cipla: Declining India sales lead to a Q1 miss
Margin improvement a silver lining, if sustained, can boost confidence
 "Cipla: Declining India sales lead to a Q1 miss")
Cipla Q1 net profit surges 24% to Rs 425 crore
The drug major had posted a net profit of Rs 343.70 cr for the corresponding period in FY17
Cipla's newly launched drug to cure severe malaria in young children
The anti-malaria drug now soon will be available in four sub-Saharan countries